Evidence map›Paper›PMID 26487951›Full record

ReviewJournal of gastrointestinal oncology2015

Trans-arterial embolisation therapies for unresectable intrahepatic cholangiocarcinoma: a systematic review.

Linda Yang, Jocelyn Shan, Leonard Shan, Akshat Saxena, Lourens Bester, David L Morris

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of gastrointestinal oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05422690 (A Phase II Single-center, Open-label, Single Arm Study of Induction Gemcitabine, Cisplatin and Durvalumab Followed by Gemcitabine, Cisplatin and Yttrium-90), which is not on this map. Cited by 19 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 2 pooled it
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05422690 phase2recruitingnot on this mapstarted 2024, after this paper: background citation

A Phase II Single-center, Open-label, Single Arm Study of Induction Gemcitabine, Cisplatin and Durvalumab Followed by Gemcitabine, Cisplatin and Yttrium-90 (Y-90) Radioembolization for the Treatment of Locally Advanced Unresectable Intrahepatic Cholangiocarcinoma

TypeinterventionalSponsorInova Health Care ServicesRan2024 to 2028Enrolled16ConditionsIntrahepatic CholangiocarcinomaArmsInduction Chemotherapy Triplet Therapy, Concurrent Y-90 treatment, Consolidation Doublet Therapy:
3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.

  1. Radiological Loco-Regional Treatments for Cholangiocarcinoma: A Systematic Review of the Literature.Liver international : official journal of the International Association for the Study of the Liver · 2026
    Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Salinomycin enhances doxorubicin sensitivity through reversing the epithelial-mesenchymal transition of cholangiocarcinoma cells by regulating ARK5.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2017
    Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Linda Yang1 Melbourne Medical School, The University of Melbourne, Victoria, Australia ; 2 Faculty of Medicine, Nursing and Health Sciences, Monash University, Victoria, Australia ; 3 Department of Surgery, St George Hospital, Kogarah, New South Wales, Australia ; 4 Department of Radiology, School of Medicine, University of Notre Dame, Darlinghurst, New South Wales, Australia.
Jocelyn Shan1 Melbourne Medical School, The University of Melbourne, Victoria, Australia ; 2 Faculty of Medicine, Nursing and Health Sciences, Monash University, Victoria, Australia ; 3 Department of Surgery, St George Hospital, Kogarah, New South Wales, Australia ; 4 Department of Radiology, School of Medicine, University of Notre Dame, Darlinghurst, New South Wales, Australia.
Leonard Shan1 Melbourne Medical School, The University of Melbourne, Victoria, Australia ; 2 Faculty of Medicine, Nursing and Health Sciences, Monash University, Victoria, Australia ; 3 Department of Surgery, St George Hospital, Kogarah, New South Wales, Australia ; 4 Department of Radiology, School of Medicine, University of Notre Dame, Darlinghurst, New South Wales, Australia.
Akshat Saxena1 Melbourne Medical School, The University of Melbourne, Victoria, Australia ; 2 Faculty of Medicine, Nursing and Health Sciences, Monash University, Victoria, Australia ; 3 Department of Surgery, St George Hospital, Kogarah, New South Wales, Australia ; 4 Department of Radiology, School of Medicine, University of Notre Dame, Darlinghurst, New South Wales, Australia.
Lourens Bester1 Melbourne Medical School, The University of Melbourne, Victoria, Australia ; 2 Faculty of Medicine, Nursing and Health Sciences, Monash University, Victoria, Australia ; 3 Department of Surgery, St George Hospital, Kogarah, New South Wales, Australia ; 4 Department of Radiology, School of Medicine, University of Notre Dame, Darlinghurst, New South Wales, Australia.
David L Morris1 Melbourne Medical School, The University of Melbourne, Victoria, Australia ; 2 Faculty of Medicine, Nursing and Health Sciences, Monash University, Victoria, Australia ; 3 Department of Surgery, St George Hospital, Kogarah, New South Wales, Australia ; 4 Department of Radiology, School of Medicine, University of Notre Dame, Darlinghurst, New South Wales, Australia.
St George Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUnresectable intrahepatic cholangiocarcinoma (ICC) portends a poor prognosis despite standard systemic treatments which confer minimal survival benefits and significant adverse effects. This study aimed to assess clinical outcomes, complications and prognostic factors of TAE therapies using chemotherapeutic agents or radiation.

methodsA literature search and article acquisition was conducted on PubMed (MEDLINE), OVID (MEDLINE) and EBSCOhost (EMBASE). Original articles published after January 2000 on trans-arterial therapies for unresectable ICC were selected using strict eligibility criteria. Radiological response, overall survival, progression-free survival, safety profile, and prognostic factors for overall survival were assessed. Quality appraisal and data tabulation were performed using pre-determined forms. Results were synthesized by narrative review and quantitative analysis.

resultsTwenty articles were included (n=929 patients). Thirty three percent of patients presented with extrahepatic metastases. After treatment, the average rate of complete and partial radiological response was 10% and 22.2%, respectively. Overall median survival time was 12.4 months with a median 30-day mortality and 1-year survival rate of 0.6% and 53%, respectively. Acute treatment toxicity (within 30 days) was reported in 34.9% of patients, of which 64.3% were mild to moderate in severity. The most common clinical toxicities were abdominal pain, nausea and vomiting, and fatigue. Multiplicity, localization and vascularity of the tumor may predict worse overall survival.

conclusionsTrans-arterial therapies are safe and effective treatment options which should be considered routinely for unresectable ICC. Consistent and standardized methodology and data collection is required to facilitate a meta-analysis. Randomized controlled trials will be valuable in the future.

Indexed as

embolizationIntrahepatic cholangiocarcinoma (ICC)survivalunresectable

Identifiers

PMID26487951
PMCPMC4570915
OpenAlexW2104175716

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.